司妥昔单抗/托珠单抗治疗HHV-8阴性多中心型Castleman病的疗效及安全性单中心回顾性分析

A Single-Center Retrospective Analysis of the Efficacy and Safety of Siltuximab/Tocilizumab in the Treatment of HHV-8-Negative Multicentric Castleman's Disease

目的旨在评估司妥昔单抗/托珠单抗治疗人疱疹病毒8型(HHV-8)阴性多中心型Castleman病的疗效及安全性。方法回顾性分析2018—2022年浙江大学附属第一医院诊断HHV-8阴性多中心型Castleman病,初始治疗使用司妥昔单抗/托珠单抗为基础方案等患者,共纳入14例患者,观察其疗效及安全性。结果治疗结果显示,14例患者中,8例患者临床症状改善,高炎症指标较前好转,复查淋巴结较前缩小,疗效达部分缓解(PR);4例患者临床症状改善不明显,疗效达疾病稳定(SD);2例患者治疗过程中出现疾病进展,疗效为疾病进展(PD)。在治疗过程中,未发现明显不良反应,患者耐受性良好。结论司妥昔单抗/托珠单抗治疗HHV-8阴性多中心型Castleman病具有显著疗效,且安全性良好。

Objective To evaluate the efficacy and safety of siltuximab/tocilizumab in the treatment of human herpesvirus 8(HHV-8)negative multicentric Castleman's disease.Methods A retrospective analysis was conducted on patients diagnosed with HHV-8-negative multicentric Castleman's disease at the First Affiliated Hospital of Zhejiang University from 2018 to 2022,who initially received Siltuximab/Tocilizumabbased treatment.A total of 14 patients were included to observe their treatment efficacy and safety.Results Among the 14 patients,8 showed clinical improvement,with reduced high inflammation markers and decreased lymph node size,achieving a partial response(PR);4 patients had no significant improvement in clinical symptoms,achieving stable disease(SD);2 patients experienced disease progression during treatment,resulting in progressive disease(PD).No significant adverse reactions were observed during the treatment,indicating good tolerability among patients.Conclusions Siltuximab/Tocilizumab treatment for multicentric Castleman's disease demonstrates significant efficacy and good safety.